TY - JOUR T1 - Dr. Genovese comments JF - The Journal of Rheumatology JO - J Rheumatol SP - 1994 LP - 1994 DO - 10.3899/jrheum.150600 VL - 42 IS - 10 AU - MARK GENOVESE Y1 - 2015/10/01 UR - http://www.jrheum.org/content/42/10/1994.abstract N2 - To the Editor:The Abatacept Comparison of sub(QU)cutaneous versus intravenous in Inadequate Responders to methotrexatE (ACQUIRE) trial was a multinational, Phase IIIb, randomized, double-blind study that evaluated the comparable efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept (ABA) over 6 months1. At Month 6, similar proportions of SC and IV ABA-treated patients achieved an American College of Rheumatology 20 … Address correspondence to Dr. M. Genovese; E-mail: genovese{at}stanford.edu ER -